Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-01 for Mild-moderate Clostridium Difficile Infection
NCT04121169Phase 2Unknown
- Sponsor
- Immunimed
- Start
- Oct 2019
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IM-01 in Clostridium difficile infection (CDI) (2 arms), sponsored by Immunimed. Primary endpoints: Clinical Response to IM-01 Treatment at 14 days and Reduce C. difficile pathogen count, spore count, and C. difficile Toxin Titers at 56 days. Status: unknown.
02
Drugs
IM-01
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04121169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121169.